NCT04993989View on ClinicalTrials.gov

A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome

CompletedOBSERVATIONAL
Enrollment

843

Participants

Timeline

Start Date

November 16, 2017

Primary Completion Date

April 18, 2018

Study Completion Date

April 18, 2018

Conditions
Functional and Motility Related Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia
Interventions
DRUG

Iberogast (STW5, BAY98-7411)

Survey without any intervention assigned in the study.

Trial Locations (1)

Unknown

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04993989 - A Pharmacy-based Study to Learn More About How Well Iberogast Works, How it Affects the Body, How it is Used, and User Satisfaction in Patients With Functional and Motility-related (Stomach and Bowel Movement-related) Gastrointestinal Diseases, Including Irritable Bowel Syndrome | Biotech Hunter | Biotech Hunter